Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer

Jane Blazeby(University Hospitals Bristol NHS Foundation Trust), Corneel Coens(European Organisation for Research and Treatment of Cancer), Thierry Conroy(Inserm), Jenny Moore(Trinity College Dublin), Orhan Sezer(Charité - Universitätsmedizin Berlin), Nazım Serdar Turhal(Marmara University), Sven D’haese(European Organisation for Research and Treatment of Cancer), Michael Koller(University Hospital Regensburg), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Andrew Bottomley(Bradford Teaching Hospitals NHS Foundation Trust), Juan Ignacio Arrarás, C W Vickery(University of Bristol), Robert K. Stuart(Memorial Sloan Kettering Cancer Center)
European Journal of Cancer
August 11, 2004
10.1016/j.ejca.2004.05.023
Cited by 225

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k